Cytovance Biologics and PolyPeptide Partner to Advance Peptide Drug Development

• Cytovance Biologics and PolyPeptide have announced a collaboration to provide integrated solutions for microbial and mammalian-expressed peptide drugs.

• The partnership combines Cytovance’s biologics expertise with PolyPeptide’s peptide synthesis capabilities to meet growing industry demand.

Cytovance Biologics and PolyPeptide have entered into a strategic collaboration to support the development and manufacturing of microbial and mammalian-expressed peptide drugs. This partnership combines Cytovance’s experience in process development and cGMP manufacturing with PolyPeptide’s expertise in complex peptide synthesis, providing drug developers with a seamless and scalable solution for peptide drug production.

The collaboration responds to increasing global demand for peptide-based therapies. Axel Schleyer, Chief Commercial Officer at Cytovance Biologics, highlighted the alignment of capabilities: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”

With a history of manufacturing over 1,000 therapeutic peptides, PolyPeptide brings robust peptide development expertise to the partnership. Trishul Shah, PolyPeptide’s Director of Business Development, commented: “The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.”

This agreement builds on previous joint efforts between the companies on specific customer projects, expanding their partnership to offer greater capacity and efficiency. It aims to fast-track new peptide products from development to market, enabling drug developers to meet evolving clinical and commercial demands.